On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
High Level Timelines of privileges regarding the commercialization and use of knowledge Timeline of privileges regarding the commercialization and use of knowledge: Part 1: before 1980 Timeline of privileges regarding the commercialization and use of knowledge: Part 2: 1980 to… Continue Reading
(More on compulsory licensing here.) This is a non-exhaustive set of provisions in US statutes that are used to for non-voluntary use of patented inventions. 28 U.S.C. 1498 – Patent and copyright cases (a) Whenever an invention described in and… Continue Reading
The proposed Regional Comprehensive Economic Partnership, known as RCEP. RCEP is a massive proposed trade agreement, some see as a rival or alternative to the TransPacific Partnership (TPP). The RCEP currently involves the ten member states of the Association of… Continue Reading
KEI follows a number of negotiations over global norms for knowledge governance. Among the multilateral fora where KEI has been particularly active are the Geneva based World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and the World Health… Continue Reading
This does not yet have links to the TPP11 negotiations and agreement, after the US left. The May 11, 2015 consolidated text on the Intellectual Property Chapter of the TPP, with country positions. August 4, 2015 Press Release The May… Continue Reading
The governments of the United States, the European Commission, Japan, Switzerland, Australia, New Zealand, South Korea, Canada, and Mexico are negotiating a trade agreement named the Anti-Counterfeiting Trade Agreement (ACTA). Despite the name, the agreement is designed to address not… Continue Reading
The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
More on Fabry here: https://keionline.org/fabry NIH rejects Fabrazyme March-In Petition December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying… Continue Reading
(More on government funded inventions here: https://keionline.org/government-funded-inventions) On December 9, 2016, the U.S. Army announced its intent to grant an exclusive license to Sanofi on patents for a U.S. Army-developed Zika vaccine. KEI and various other non-profit groups have filed… Continue Reading